Anti-A2AR combined with either anti-PD-L1 or anti-CTLA-4 therapy showed efficacious tumor inhibition and led to up to 90% of tumors being eliminated in MC38 tumor-bearing mice that did not respond fully to anti-PD-L1 or anti-CTLA-4 monoclonal antibodies alone. The gene discussed is CTLA4; the disease is neoplasm.